Can the Endocannabinoid System Protect Muscle Health?

Muscle loss is often treated as a secondary consequence of chronic disease. Cancer, diabetes, obesity, cardiovascular disease, kidney disease, liver disease, and inflammatory bowel disease can all reduce muscle mass or strength. However, the biological processes connecting these conditions to skeletal muscle degeneration remain incompletely understood.

A new narrative review published in Experimental Gerontology¹ proposes that the endocannabinoid system may be part of that missing connection. After examining human, animal, and cell-based research, the authors identified recurring links between endocannabinoid system dysregulation, non-communicable diseases, and deteriorating muscle health.

This does not mean cannabis has been shown to prevent muscle wasting. In fact, some of the most promising experimental approaches work by blocking a cannabinoid receptor rather than activating it. The study instead suggests that precisely controlling the body’s cannabinoid signaling could eventually help address both chronic disease and the muscle degeneration that often accompanies it.

Why Muscle Loss Matters in Chronic Disease

Skeletal muscle does considerably more than move the body. It helps regulate glucose and lipid metabolism, produces heat, supports breathing, and provides an important reserve during illness. When muscle tissue deteriorates, patients can become weaker, less mobile, and less able to tolerate treatment.

This problem appears across a wide range of conditions. Cancer cachexia can cause severe involuntary weight and muscle loss. Chronic kidney and liver diseases can promote inflammation and protein breakdown. Diabetes may interfere with muscle metabolism and regeneration, while cardiovascular disease can reduce physical capacity and contribute to inactivity.

The scale of the underlying disease burden is enormous. According to the World Health Organization, non-communicable diseases caused at least 43 million deaths in 2021. Cardiovascular disease, cancer, chronic respiratory disease, and diabetes accounted for most of them.

Preserving muscle is therefore not simply a fitness goal. It can affect independence, metabolic health, treatment tolerance, recovery, and mortality.

How the Endocannabinoid System Regulates the Body

The endocannabinoid system, or ECS, is a signaling network found throughout the brain and peripheral tissues. Its major components include endocannabinoids produced by the body, enzymes that create or break down those molecules, and receptors that respond to them.

Two of the best-known endocannabinoids are anandamide, also called AEA, and 2-arachidonoylglycerol, or 2-AG. They interact with cannabinoid receptor 1 and cannabinoid receptor 2, commonly shortened to CB1 and CB2. Other receptors and molecular targets can also participate.

CB1 is widely associated with the brain, appetite, and the intoxicating effects of THC, but it is also present in peripheral tissues. CB2 is more closely associated with immune activity and inflammation. Together, these receptors influence processes ranging from energy metabolism and pain to fibrosis, appetite, and immune responses.

Cannabis interacts with this system because plant cannabinoids can activate or influence some of the same pathways. However, THC, CBD, synthetic cannabinoids, naturally produced endocannabinoids, receptor blockers, and enzyme inhibitors are not interchangeable. Each may produce different effects depending on the receptor, tissue, dose, and disease involved.

The Proposed ECS-Disease-Muscle Connection

The review found altered endocannabinoid levels, receptor expression, or enzyme activity across every disease category it examined. These changes did not always move in the same direction, but circulating AEA or 2-AG levels were commonly elevated in people with non-communicable diseases, with kidney disease being a notable exception.

At the same time, those conditions frequently displayed familiar signs of skeletal muscle degeneration:

• Loss of muscle mass
• Reduced strength
• Chronic inflammation
• Impaired muscle regeneration

This overlap led the authors to propose an ECS-disease-muscle axis. Under this model, chronic disease changes endocannabinoid signaling, and those changes may indirectly or directly influence skeletal muscle. The relationship could also work in both directions because unhealthy muscle can worsen metabolism and systemic inflammation.

Importantly, elevated endocannabinoid levels in blood do not prove that cannabinoid signaling is elevated inside muscle. Receptor density, local enzyme activity, tissue-specific ligand concentrations, and disease stage can all change the result. The proposed axis is therefore a research framework, not a confirmed clinical mechanism.

What Happens When Cannabinoid Receptors Are Modified?

The clearest muscle-related results involved CB1 antagonism, meaning the receptor was blocked or its activity reduced. In human muscle cells, a CB1 antagonist increased protein synthesis and activated proteins associated with anabolic signaling. In mouse models, CB1-blocking drugs reduced muscle loss caused by corticosteroid exposure or immobilization.

CB1 antagonism was also associated with better grip strength, improved muscle regeneration, and lower expression of inflammatory markers in certain animal models. Conversely, activating CB1 appeared more likely to interfere with muscle differentiation, although results varied by model.

CB2 activation produced a different pattern. In injured muscle, CB2 agonists increased markers connected with muscle formation and regeneration. The evidence suggests that blocking CB1 and activating CB2 may sometimes produce complementary benefits, but neither approach has been adequately validated in people experiencing disease-associated muscle loss.

Why This Is Not Evidence That Cannabis Builds Muscle

The distinction between the endocannabinoid system and cannabis products is central to understanding this research. The paper does not show that smoking cannabis, consuming THC, or taking commercial CBD products will preserve muscle.

THC is a partial agonist at CB1 and CB2 receptors. Yet much of the muscle-protective evidence summarized in the review involved CB1 antagonism, which moves signaling in the opposite direction. This helps explain why translating receptor biology into consumer advice would be misleading.

There are limited exceptions worth investigating. In a laboratory model of cancer cachexia, THC and other CB1 or CB2 agonists protected human muscle cells from degeneration. Clinical studies of THC or combined THC and CBD in cancer patients have also examined appetite, pain, and quality of life, but the results have been mixed.

The National Cancer Institute recognizes that cannabis and cannabinoids have been studied for cancer-related pain, nausea, and appetite loss. That symptom relief should not be confused with evidence that cannabis reverses cachexia or directly rebuilds muscle.

The distinction also has practical relevance as medical programs expand. Kentucky, for example, recently added cachexia and wasting syndrome to its recognized medical cannabis conditions. Such policies can provide symptom-management access without establishing cannabis as a treatment for the biological drivers of wasting.

Why Earlier CB1 Drugs Failed

Blocking CB1 is not a new therapeutic idea. Rimonabant was approved in Europe for obesity after producing meaningful weight loss and improvements in some metabolic measures. It was later withdrawn amid concerns about psychiatric adverse effects associated with blocking CB1 in the brain.

The episode illustrates the central challenge of ECS-based medicine. The same receptor can perform different functions in the brain, liver, fat, muscle, and other tissues. A drug that produces the desired metabolic effect may also disrupt mood or behaviour if it crosses the blood-brain barrier.

Researchers are now investigating peripherally restricted CB1 antagonists designed to act outside the brain. Other possibilities include negative allosteric modulators, selective CB2 agonists, and drugs that alter the enzymes responsible for producing or degrading endocannabinoids. These approaches seek to tune the system more precisely instead of switching a widely distributed receptor fully on or off.

Similar scientific caution applies to individual plant cannabinoids. Recent research covered by MyCannabis found that CBD reduced atherosclerotic plaque in male mice but not females, illustrating how cannabinoid effects can depend on sex, formulation, dose, and biological context.

Muscle Protection Will Probably Require Combination Therapy

Even if ECS-targeted drugs eventually prove useful, they are unlikely to replace exercise, nutrition, rehabilitation, or treatment of the underlying disease. Muscle loss results from multiple overlapping pressures, including inflammation, inactivity, hormonal changes, impaired blood flow, inadequate nutrition, and altered protein metabolism.

The most realistic future application may therefore be combination therapy. A receptor-targeted drug might reduce inflammatory or catabolic signaling while resistance exercise stimulates muscle adaptation and nutritional support supplies the material needed for repair.

The gut microbiome could add another layer. It communicates with the endocannabinoid system and has independently been linked to muscle mass, metabolism, and inflammation. This raises the possibility that the proposed ECS-disease-muscle axis is part of a larger network involving the gut, immune system, and metabolic organs.

What Researchers Need to Prove Next

The paper’s hypothesis remains several steps away from clinical use. Most intervention evidence comes from cultured cells or animals, and only two studies directly investigated ECS modulation in muscle within a non-communicable disease model.

Researchers must determine whether the observed mechanisms operate in human patients, whether benefits differ between men and women, and which diseases are suitable for each intervention. A therapy that encourages weight loss could be useful in obesity but dangerous in cancer cachexia, where patients have little physiological reserve.

Future trials will also need standardized methods for measuring circulating endocannabinoids. Without consistent collection, processing, and analytical techniques, it is difficult to establish reference ranges or determine whether AEA and 2-AG can become useful clinical biomarkers.

The most important conclusion is therefore not that cannabinoids cure muscle wasting. It is that skeletal muscle should be considered when scientists investigate the endocannabinoid system in chronic disease. If the proposed connection holds up in humans, carefully targeted ECS therapies could eventually help protect the body from both the primary disease and one of its most damaging secondary consequences.

References:

¹ Vanderbeke, K., Dalle, S., & Koppo, K. (2026). Endocannabinoid system dysregulation in non-communicable diseases: Implications for skeletal muscle health. Experimental Gerontology, 113312. https://doi.org/10.1016/j.exger.2026.113312